We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Stellar Biotechnologies Presents at Annual 2013 NSF Conference
News

Stellar Biotechnologies Presents at Annual 2013 NSF Conference

Stellar Biotechnologies Presents at Annual 2013 NSF Conference
News

Stellar Biotechnologies Presents at Annual 2013 NSF Conference

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Stellar Biotechnologies Presents at Annual 2013 NSF Conference"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Stellar Biotechnologies, Inc. has announced the presentation of a poster at the Annual 2013 National Science Foundation (NSF) Conference in Baltimore, MD highlighting the Company’s achievements in developing methods related to the sustainable cultivation of the ocean mollusk that is the sole source for Keyhole Limpet Hemocyanin (KLH).

KLH protein is only derived from the Giant Keyhole Limpet (Megathura crenulata), a scarce sea mollusk native to the Pacific Coast waters off California.

The poster titled “Megathura crenulata Post Larval Culture – Bottleneck for a Valuable Medical Resources” was presented by Brandon Lincicum, Stellar’s Executive Director of Aquaculture and Operations.

The presentation recapped innovations that have allowed Stellar to achieve, for the first time in the KLH industry, systems and processes that protect and sustain multiple generations of the Giant Keyhole Limpet in land-based aquaculture.

These accomplishments are critical to supplying enough clinical-quality KLH to meet the future demands of pharmaceutical companies and researchers.

Stellar’s work was partially supported by NSF SBIR Phase I/II, Phase IIB and prestigious Technology Enhancement Commercial Partnership (TECP) funding.

“Stellar now has the world’s only demonstrated aquaculture technology for sustainable growth and cultivation of Megathura crenulata and production of KLH,” said Lincicum. “It was gratifying to present our industry-leading accomplishments at the prestigious NSF conference.”

Advertisement